{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.9","upperLimit":"99.6","value":"83.3"},{"groupId":"OG001","lowerLimit":"35.9","upperLimit":"99.6","value":"83.3"},{"groupId":"OG002","lowerLimit":"2.5","upperLimit":"100","value":"100"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"97.5","value":"0"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm A (VR-DA-EPOCH) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1)","id":"OG000","title":"Phase I: VR-DA-EPOCH, Dose Level 1"},{"description":"Arm A (VR-DA-EPOCH) with Vorinostat at 400 mg once a day on days 1-5 of a cycle (Phase I Dose Level 2)","id":"OG001","title":"Phase I: VR-DA-EPOCH, Dose Level 2"},{"description":"Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual.","id":"OG002","title":"Phase I: Arm C (VR-CHOP) Dose Level 1"}],"paramType":"NUMBER","populationDescription":"Eligible participants who completed at least 1 cycle of treatment.","reportingStatus":"POSTED","timeFrame":"Up to 2 years post treatment","title":"Tumor Response (Phase I)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}